Division of Urology

Thomas J. Polascik, MD

Associate Professor of Surgery

Department:
Surgery

Division:
Urology

Mailing Address:
DUMC 2804 Durham, NC 27710

Telephone:
919-684-2446

Office Telephone:
919-684-4946

Fax:
919-684-5220

Training:
MD, University of Chicago Pritzker School of Medicine (Illinois), 1991

Fellowship:
Urologic Oncology, Johns Hopkins Hospital (Maryland), 1997-1998

Residency:
General Surgery, Johns Hopkins Hospital (Maryland), 1991-1993

Clinical Interests:
Robotic nerve-sparing prostate surgery; nerve-sparing focal therapy (cryosurgery, HIFU, hemiablation) for prostate cancer; minimally invasive (robotic, laparoscopic, cryotherapy) surgery for kidney tumors; urologic oncology

Research Interests:
Prostate cancer imaging
Focal therapy of prostate cancer
Prostate cancer outcomes
Minimally invasive surgery
Nerve sparing cryotherapy

Publications:
Stein AJ, Mayes JM, Mouraviev V, Chen VH, Nelson RC, Polascik TJ. Persistent contrast enhancement several months after laparoscopic cryoablation of the small renal mass may not indicate recurrent tumor. J Endourol. 2008 Nov;22(11):2433-9.

Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, Moul JW. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU Int. 2008 Jul;102(1):28-32.

Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, Moul JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008 Oct;54(4):785-93.

Schroeck FR, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, Moul JW, Krupski TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008 Nov 15;113(10):2687-94.

Polascik TJ. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis. 2008;11(1):13-9.

Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag. 2008 Feb;4(1):261-8.

Polascik TJ, Mouraviev V. Focal therapy for prostate cancer. Curr Opin Urol. 2008 May;18(3):269-74.

Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008 Sep 15;68(13):1380-6.

Polascik TJ, Mayes JM, Mouraviev V. From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. Oncology (Williston Park). 2008 Jul;22(8):900-6; discussion 906-7, 914.

Mouraviev V, Broadwater G, Sun L, Mayes JM, Moul JW, Polascik TJ. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? Urology. 2008 Jun;71(6):1020-3.

Megwalu II, Ferguson GG, Wei JT, Mouraviev V, Polascik TJ, Taneja S, Black L, Andriole GL, Kibel AS. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int. 2008 Aug 5;102(5):546-50.

Mayes JM, Mouraviev V, Polascik TJ. Impact of a cryotherapy training workshop on the adoption and utilization of cryotherapy in the community setting. Can J Urol. 2008 Aug;15(4):4147-52.

Koontz BF, Mouraviev V, Johnson JL, Mayes J, Chen SH, Wong TZ, Anscher MS, Sun L, Moul J, Polascik TJ. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):358-61.

Isariyawongse BK, Sun L, Bañez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008 Oct;72(4):882-6.

Habib AS, White WD, El Gasim MA, Saleh G, Polascik TJ, Moul JW, Gan TJ. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesth Analg. 2008 Sep;107(3):999-1004.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87.

Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, Polascik TJ, Ruffin MT 4th, Vollmer RT. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials. 2008;5(3):262-72.

Chen VH, Mayes JM, Mouraviev V, Polascik TJ. Urothelial sloughing with obstruction after laparoscopic cryoablation of small renal carcinoma in solitary kidney. Urology. 2008 Sep;72(3):716.e1-2.

Chen VH, Mayes JM, Madden JF, Stein AJ, Mouraviev V, Polascik TJ. The effect of cryoablation on the histologic interpretation of intraoperative biopsy of small clear cell renal carcinoma and renal oncocytoma. J Endourol. 2008 Aug;22(8):1617-21.

Tseng TY, Cancel QV, Fesperman SF, Kuebler HR, Sun L, Robertson CN, Polascik TJ, Moul JW, Vieweg J, Albala DM, Dahm P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. J Urol. 2007 Apr;177(4):1318-23.

Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007 Jan 22.

Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology. 2007 Jul;70(1):117-21.

Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. Short Term Clinical Outcome after Laparoscopic Cryoablation of the Renal Tumor < or = 3.5 cm. Technol Cancer Res Treat. 2007 Dec;6(6):621-4.

Polascik TJ, Mouraviev V. The rise of ablative technologies for treating the small renal mass. Eur Urol. 2007 Sep;52(3):636-8.

Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007 Dec;70(6):1141-5.

Mouraviev V, Nosnik I, Sun L, Robertson CN, Walther P, Albala D, Moul JW, Polascik TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007 Feb;69(2):311-4.

Mouraviev V, Nosnik I, Robertson C, Albala D, Walther P, Polascik TJ. Comparative financial analysis of minimally invasive surgery to open surgery for small renal tumours < or =3.5 cm: a single institutional experience. Eur Urol. 2007 Mar;51(3):715-20; discussion 720-1.

Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007 Aug 15;110(4):906-10.

Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat. 2007 Apr;6(2):91-5.

Mouraviev V, Joniau S, Van Poppel H, Polascik TJ. Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol. 2007 Feb;51(2):328-36.

Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007 Feb;177(2):499-503; discussion 503-4.

Marguet C, Raj GV, Brashears JH, Anscher MS, Ludwig K, Mouraviev V, Robertson CN, Polascik TJ. Rectourethral fistula after combination radiotherapy for prostate cancer. Urology. 2007 May;69(5):898-901.

Chen SH, Mouraviev V, Raj GV, Marguet CG, Polascik TJ. Ureteropelvic junction obliteration resulting in nephrectomy after radiofrequency ablation of small renal cell carcinoma. Urology. 2007 May;69(5):982.e3-5.

Chen SH, Mouraviev V, Mayes JM, Polascik TJ. Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer. Can J Urol. 2007 Aug;14(4):3646-8.

Wiygul JB, Lallas C, Silverstein A, Polascik TJ. Ovarian hyperstimulation causing ureteral obstruction in a pregnant woman. Urology. 2006 May;67(5):1085.e5-6.

Raj GV, Yowell C, Madden JF, Nosnik I, Mouraviev V, Polascik TJ. Malignant cystic nephroma. Can J Urol. 2006 Dec;13(6):3348-50.

Nosnik IP, Mouraviev V, Nelson R, Polascik TJ. Multiple nephron-sparing procedures in solitary kidney with recurrent, metachronous, nonfamilial renal cell carcinoma. Urology. 2006 Dec;68(6):1343.e1-3.

Mouraviev V, Polascik TJ. Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol. 2006 May;16(3):152-6.

Mouraviev V, Polascik TJ. Editorial comment. J Urol. 2006 Jun;175(6):2169.

Mouraviev V, Evans B, Polascik TJ. Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach. Prostate Cancer Prostatic Dis. 2006;9(1):99-101.

Auge BK, Santa-Cruz RW, Polascik TJ. Effect of freeze time during renal cryoablation: a swine model. J Endourol. 2006 Dec;20(12):1101-5.

Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005 Feb;184(2):676-80.

Wiygul JB, Evans BR, Peterson BL, Polascik TJ, Walther PJ, Robertson CN, Albala DM, Demark-Wahnefried W. Supplement use among men with prostate cancer. Urology. 2005 Jul;66(1):161-6.

Weizer AZ, Raj GV, O'Connell M, Robertson CN, Nelson RC, Polascik TJ. Complications after percutaneous radiofrequency ablation of renal tumors. Urology. 2005 Dec;66(6):1176-80.

Raj GV, Brashears JH, Anand A, Paulson DF, Polascik TJ. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? Urology. 2005 Feb;65(2):332-6.

Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005 Nov;66(5):1054-9.

Brashears JH 3rd, Raj GV, Crisci A, Young MD, Dylewski D, Nelson R, Madden JF, Polascik TJ. Renal cryoablation and radio frequency ablation: an evaluation of worst case scenarios in a porcine model. J Urol. 2005 Jun;173(6):2160-5.

Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9.

Demark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology. 2004 May;63(5):900-4.

Santa-Cruz RW, Auge BK, Lallas CD, Preminger GM, Polascik TJ. Use of bipolar laparoscopic forceps to occlude and transect the retroperitoneal vasculature: a porcine model. J Endourol. 2003 Apr;17(3):181-5.

Raj GV, Reddan DJ, Hoey MF, Hoey MB, Polascik TJ. Management of small renal tumors with radiofrequency ablation. Urology. 2003 Jan;61(1):23-9.

Raj GV, Ellington KS, Polascik TJ. Autoimmune testicular vasculitis. Urology. 2003 May;61(5):1035.

Polascik TJ and Marshall FF:  Surgery for neoplastic involvement of the renal vein and inferior vena cava.  In:  Management of Urologic Malignancies.  Eds. Hamdy FC, Basler JW, Neal DE and Catalona WJ.  Churchill Livingstone, London, 2002

Polascik TJ and Marshall FF:  Partial nephrectomy.  In:  Management of Urologic Malignancies.  Eds. Hamdy FC, Basler JW, Neal DE and Catalona WJ.  Churchill Lovingstone, London, 2002.

Munver R, Threatt CB, Delvecchio FC, Preminger GM, Polascik TJ. Hypertonic saline-augmented radiofrequency ablation of the VX-2 tumor implanted in the rabbit kidney: a short-term survival pilot study. Urology. 2002 Jul;60(1):170-5.